A Prospective,Multi-Center,Randomized Control Trial of Preoperative Hepatic and Regional Arterial Chemotherapy(PHRAC) Using Oxaliplatin, Fluorodeoxyuridine(FUDR) and Mitomycin C(MMC) to Prevent Postoperative Liver Metastasis of Colorectal Cancer
We administered FUDR, MMC and Oxaliplatin as preoperative hepatic and regional arterial
chemotherapy (PHRAC) to patients with Stage II or Stage III colorectal cancer without
apparent liver metastasis based on a thorough preoperative evaluation. The study endpoints
were disease-free survival, overall survival, and liver metastasis-free survival as
evaluated by intent-to-treat analysis.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
5 years disease-free survival
5 years after operation
Yes
jianmin xu, MD
Study Chair
department of general surgery, zhongshan hospital, fudan university
China: Food and Drug Administration
2008-46
NCT00643877
December 2008
December 2014
Name | Location |
---|